Approval for new alzheimer’s drug developed at UZH



Congratulations to the UZH spinoff Neurimmune, founded by the two UZH professors Roger Nitsch and Christoph Hock. Together with UZH researchers, Neurimmune succeeded in identifying protective antibodies against the protein amyloid, which can cause Alzheimer’s disease. The active ingredient aducanumab, has now been approved for use in the United States.

This innovation is an excellent example of the successful transfer of university research into application, as UZH President Michael Schaepman says: “Neurimmune shows that innovative UZH spin-offs bring great value to society and can establish themselves in the marketplace.”

Read the more in the UZH press release.